ChemoTech changes language for information disclosure
Scandinavian ChemoTech AB has decided to change language from Swedish to English for disclosure of information. The change will take…
0,135€
-0,30%
Echtzeit-Aktienkurs Scandinavian ChemoTech AB
Bid:
Ask:
Nachrichten zur Scandinavian ChemoTech AB Aktie
Scandinavian ChemoTech AB (publ) brings forward interim report
Scandinavian ChemoTech AB (publ) ("ChemoTech") has decided to bring forward the publication of the interim report for the third quarter…
Scandinavian ChemoTech signs distribution agreement for Chile with Lambertis Corporation SA
ChemoTech has today signed a distribution agreement with Lambertis Corporation SA "Lambertis" in Chile, which means that ChemoTech is now…
(Retransmission) Vetiqure AB, the Animal care division of Scandinavian ChemoTech and Royal Veterinary College, to establish a Centre of Excellence for TSE
Retransmission of press release that was issued on August 26, 2023 at 11:30 CET.
Following a six-month evaluation, the Royal Veterinary…
Vetiqure AB, the Animal care division of Scandinavian ChemoTech and Royal Veterinary College, to establish a Centre of Excellence for TSE
Following a six-month evaluation, the Royal Veterinary College (RVC) will now aquire the vetIQure™ system and make Tumour Specific Electroporation…
Scandinavian ChemoTech receives a patent in Japan for its unique tumor-specific and dynamic cancer treatment
ChemoTech has been notified that the companys previously approved patent application regarding the unique functions that today relate to the…
Scandinavian ChemoTech has renewed existing loans from external lenders, larger shareholders and members of the board and CEO
Today ChemoTech signed an extension of the existing credit lines amounting to 6 MSEK, which provides the company with 2…
Correction: ChemoTech’s Animal Care division awarded supplier contract with MedVet; receives an 1,3 MSEK order in the USA
Earlier version of this press release was sent in error, MedVet was incorrectly stated to have selected ChemoTech as "preferred…
ChemoTech’s Animal Care division receives a 1.3 MSEK order and becomes preferred supplier to leading veterinary group in the USA
VQ Animal Care Inc, our US subsidiary, has received a significant order of MSEK 1.3 from the MedVet Group. This…
Scandinavian ChemoTech publishes an interview with newly appointed chairman of the board Robin Sukhia
On May 16, 2023, Robin Sukhia was elected as the new chairman of the board for Scandinavian ChemoTech. In an…
Scandinavian ChemoTech - Updates from our animal care unit
Dr Omar Maher, an internationally renowned equestrian veterinarian, at the Atlantic Equine Services in Florida, performed his first TSE (Tumour…
Scandinavian ChemoTech Animal Care unit installs its first commercial installation at Evidensia
Vetiqure AB installs the vetIQure™ system at Evidensia Specialist Horse Hospital in Strömsholm with a rental agreement that can generate…
Warrants of series TO3 were subscribed to approximately 65.14 percent and Scandinavian ChemoTech receives approximately SEK 7.44 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,…
Scandinavian ChemoTech updates its focus in Human Care as new management make progress in India
In the wake of the pandemic, Scandinavian ChemoTech strengthened its management to improve on the ability to faster reach success…
The last day of trading in the warrants of series TO3B in Scandinavian ChemoTech AB is today, April 20, 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,…
The exercise price for subscription of warrants of series TO3A and TO3B in Scandinavian ChemoTech AB has been set at SEK 4.79 per share, the exercise period begins April 11
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,…
Scandinavian ChemoTech’s Animal Care division receives the final order confirmation from Australia for leading equine centre research project
After having secured ethics approval for a case series at Agnes Banks Equine Clinic, an Apiam Animal Health Centre, which…
Scandinavian ChemoTech provides update on pancreas patients in Ukraine – aims for multinational TSE-studies in cooperation with partners as the next step
In September 2022, two locally advanced pancreatic cancer patients received TSE treatment at Ulis Hospital in Ukraine by open surgery.…
Scandinavian ChemoTech receives a granted patent in the US
Scandinavian ChemoTech has been notified that the patent authority in the US has approved the Companys patent relating to the…
Scandinavian ChemoTech receives new approval in Japan for its TSE for deep seated tumours
Scandinavian ChemoTech has received the final approval for its DEEPC patent application in Japan. The patent protects the innovation used…
Scandinavian ChemoTech participates and presents at the LSI Emerging Medtech Summit in California, USA
Scandinavian ChemoTech and CEO Mohan Frick will present the companys tumor-specific electroporation (TSE) at the LSI Emerging Medtech Summit 2023…
Scandinavian ChemoTech AB (publ) carries out a directed share issue and receives approximately 2.02 MSEK
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,…
Scandinavian ChemoTech publishes clinical strategy update from Medical Director Dr. Suhail Mufti
Scandinavian ChemoTech has published an updated clinical strategy from the company´s Medical Director Dr. Suhail Mufti.
The presentation can be accessed…
TSE treatments at the Royal Veterinary College shows very promising results
LUND, Sweden, Jan. 24, 2023 /PRNewswire/ -- Scandinavian ChemoTechs fully owned subsidiary Vetiqure receives very promising updates from the veterinarians…
TSE treatments at the Royal Veterinary College shows very promising results
Scandinavian ChemoTechs fully owned subsidiary Vetiqure receives very promising updates from the veterinarians at the Royal Veterinary College (RVC), who…
Scandinavian ChemoTech presents at Redeye Fight Cancer Day
On January 19, 2023, Scandinavian ChemoTechs CEO Mohan Frick will present the company and its Tumour Specific Electroporation™ (TSE) technology…
Pancreatic cancer patients in Ukraine treated with Tumour Specific Electroporation™ (TSE) are continuing to improve
Scandinavian ChemoTech has received a new report from Ulis Hospital Ukraine, which states that the quality of life of the…